Poor
Not Aligned
Patient Risk:
Low
Summary
The provided AI-generated statements focus on long-term efficacy and weight regain with discontinuation. The supplied FDA label excerpts provided in the prompt address only thyroid C-cell tumor risk/contraindications and do not support the long-term efficacy, maintenance, plateau, or weight regain claims. Therefore, most statements are unsupported relative to the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
Wegovy’s effectiveness is maintained over long-term treatment in the clinical trial program that studied sustained weight management.
No long-term efficacy/maintenance data are present in the supplied label excerpts.
In the STEP trials, participants who continued semaglutide generally maintained a large portion of the weight loss achieved earlier rather than reverting to baseline as quickly as they did when treatment stopped.
The supplied label excerpts do not discuss STEP trials or comparisons of continued vs stopped therapy.
Trials that follow patients for about 2 years (or longer) found that ongoing semaglutide treatment continues to produce additional weight loss or preserves much of the initial weight reduction through the maintenance period.
No 2-year/longer maintenance efficacy findings are included in the supplied label excerpts.
Stopping semaglutide is associated with weight regain.
No discontinuation/weight regain statements are included in the supplied label excerpts.
In the STEP program, people assigned to placebo after stopping semaglutide regained weight over time.
No STEP program placebo-after-discontinuation efficacy results are included in the supplied label excerpts.
In the STEP program, people who stayed on semaglutide generally continued to hold weight loss.
No STEP program ongoing-treatment efficacy statements are included in the supplied label excerpts.
Long-term efficacy of Wegovy depends on continuing therapy, not just starting it.
No label excerpt provided addresses duration dependence or efficacy requiring continued therapy.
For chronic weight management, guidelines and prescribing information typically treat GLP-1-based anti-obesity medications as long-term therapies.
The supplied label excerpts do not provide guidance about treating GLP-1 anti-obesity medications as long-term therapies.
Weight loss without ongoing treatment is difficult to sustain for chronic weight management.
No such statement appears in the supplied label excerpts.
“Efficacy maintained” generally means maintained under continued dosing, not a one-time effect.
This interpretive/general statement is not supported by the supplied label excerpts.
In practice, “long term” in the Wegovy data usually refers to multi-year follow-up, commonly around 2 years in the pivotal development program.
The supplied label excerpts do not discuss what “long term” means in Wegovy data or that it is commonly ~2 years.
The duration of about 2 years is long enough to show the difference between continued semaglutide use versus stopping, including how much weight is regained after discontinuation.
No discontinuation or weight regain comparative evidence is included in the supplied label excerpts.
Some individuals respond less than others.
No label excerpt provided addresses variability of response.
Weight loss typically plateaus over time for many patients.
No label excerpt provided describes plateauing behavior over time.
Average results remain strong but individual trajectories vary.
No label excerpt provided describes average results or individual trajectory variability.
Differences in adherence, dose titration, baseline metabolic factors, and tolerability affect individual weight loss trajectories.
No label excerpt provided discusses adherence, titration effects, metabolic factors, or tolerability as determinants of trajectory.
Some people need dose adjustments or stop due to side effects.
No label excerpt provided discusses dose adjustments or discontinuation due to side effects.
Contradictions
Important Omissions
If the intent was to discuss thyroid C-cell tumor risk, the provided statements did not mention the label’s contraindication criteria (personal/family history of MTC or MEN 2) or the specific counseling/monitoring language present in the supplied excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The unsupported statements are largely about efficacy maintenance and weight regain; while these could misinform expectations, the supplied label excerpts provided do not contain the claims needed to assess them. No specific contraindication or safety-warning facts from the long list were provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unsupported by the specific FDA label excerpts supplied in the prompt (which only address thyroid C-cell tumor risk/contraindications).
Suggested Improvement
Limit statements to what is explicitly supported by the provided label text. For thyroid C-cell tumor risk, cite the supplied contraindications (personal/family history of MTC or MEN 2) and counseling language from Sections 5.1 and 17; do not assert STEP trial maintenance/weight regain conclusions without corresponding label excerpts.